A carregar...
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
PURPOSE: To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin. METHODS: Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Sche...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3400085/ https://ncbi.nlm.nih.gov/pubmed/21140147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1536-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|